The difference in our observations compared to Guerra et al. [20] who found an increase of TROP2 in metastatic lesions could be explained by the usage of different antibodies, the inclusion of a high number of rectal cancer, and the scoring approach. This evidence concerns the gene TACSTD2 and rectal cancer.